Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents

Badrud Duza Mohammad 1, Mirza Shahed Baig 2, Neeraj Bhandari 3, Falak A. Siddiqui 4, Sharuk L. Khan 4,*, Zubair Ahmad 5,6, Farhat S. Khan 6, Priti Tagde 7 and Philippe Jeandet 8,*

1 Department of Pharmaceutical Chemistry, G R T Institute of Pharmaceutical Education and Research, GRT Mahalakshmi Nagar, Tiruttani 631209, Tamil Nadu, India
2 Department of Pharmaceutical Chemistry, Y. B. Chavan College of Pharmacy, Aurangabad 431001, Maharashtra, India
3 Arni School of Pharmacy, Arni University, Kathgarh, Indora 176401, Himachal Pradesh, India
4 Department of Pharmaceutical Chemistry, N.B.S. Institute of Pharmacy, Ausa 413520, Maharashtra, India
5 Unit of Bee Research and Honey Production, Faculty of Science, King Khalid University, P.O. Box 9004, Abha 61413, Saudi Arabia
6 Biology Department, College of Arts and Sciences, Dehran Al-Junub, King Khalid University, P.O. Box 9004, Abha 61413, Saudi Arabia
7 Patel College of Pharmacy, Madhyanchal Professional University, Bhopal 462044, Madhya Pradesh, India
8 Research Unit Induced Resistance and Plant Bioprotection, University of Reims, USC INRAe 1488, SFR Condorcet FR CNRS 3417, 51687 Reims, France

* Correspondence: sharique.4u4@gmail.com (S.L.K.); philippe.jeandet@univ-reims.fr (P.J.)

Abstract: Dipeptidyl peptidase-IV (DPP-IV) inhibitors, often known as gliptins, have been used to treat type 2 diabetes mellitus (T2DM). They may be combined with other medications as an additional treatment or used alone as a monotherapy. In addition to insulin, sulfonylureas, thiazolidinediones, and metformin, these molecules appear as possible therapeutic options. Oxadiazole rings have been employed in numerous different ways during drug development efforts. It has been shown that including them in the pharmacophore increases the amount of ligand that may be bound. The exceptional hydrogen bond acceptor properties of oxadiazoles and the distinct hydrocarbon bonding potential of their regioisomers have been established. Beside their anti-diabetic effects, oxadiazoles display a wide range of pharmacological properties. In this study, we made the assumption that molecules containing oxadiazole rings may afford a different approach to the treatment of diabetes, not only for controlling glycemic levels but also for preventing atherosclerosis progression and other complications associated with diabetes. It was observed that oxadiazole fusion with benzothiazole, 5-(2,5,2-trifluoroethoxy) phenyl, β-homophenylalanine, 2-methyl-2-{5-(4-chlorophenyl), diamine-bridged bis-coumarinyl, 5-aryl-2-(6′-nitrobenzofuran-2′-yl), nitrobenzofuran, and/or oxindole leads to potential anti-diabetic activity.

Keywords: oxadiazole; sulfonylureas; DPP-IV inhibitors; diabetes mellitus; peptidomimetics

1. Introduction

Dipeptidyl peptidase-IV (DPP-IV) inhibitors, often known as gliptins, are a class of oral anti-diabetic medications that have been given approval by the Food and Drug Administration (FDA) to treat individuals with type 2 diabetes mellitus (T2DM) [1]. Following oral ingestion of food, the production of incretin hormones, which are hormones that are vital for maintaining glucose homeostasis, occurs in the gut. These hormones are the targets through which these drugs act [2]. Independent of the incretin pathway, in addition to their antihyperglycemic activities, this family of drugs also displays antihypertensive properties [3], anti-inflammatory effects [4], and antiapoptotic effects [5], as well as immunomodulatory effects [6,7] on the heart, kidneys, and blood vessels. A number of studies
have demonstrated that this class of molecules may also be useful for treating transplant patients who have acquired new-onset diabetes after their transplantation (NODAT). These molecules may be combined with other medications as an additional treatment or used alone as a monotherapy. Sulfonylureas, thiazolidinediones, and metformin are also possible therapeutic options in addition to insulin [8,9]. Iminosugars represent a kind of polyhydroxylated secondary or tertiary amines that mimic monosaccharide sugars, but which contain nitrogen in lieu of oxygen in the ring. Iminosugars constitute a wide variety of different types of small organic molecules. These molecules belong to the class of pyrrolidines, piperidines, azepanes, nortropanes, pyrrolizidines, and indolizidines. The capacity of iminosugars to function as inhibitors of glycosidases and glycosyltransferases constituted the first role they were utilized in. These inhibitors work mostly through competitive inhibition and are mainly used to treat diabetes [10–14].

The glucagon-like peptide-1 (GLP-1) has recently emerged as a possible target for T2DM treatment. GLP-1 is produced by the gut after a meal, enhancing insulin output. It has been demonstrated that increased levels of GLP-1 may contribute to a better glycemic control in T2DM individuals. DPP-IV controls the activity of GLP-1 by cleaving the N-terminus of GLP-1 [7–36]-amide to generate inert GLP-1 [9–36]-amide. The quantity of GLP-1 in the circulation may be increased by inhibiting DPP-IV [15]. As a result, a significant amount of time and effort has been dedicated to the research of DPP-IV inhibitors as potential treatments of T2DM. Sitagliptin [16] is one of these drugs, and it has been available in the United States since 2006 as the first FDA-approved DPP-IV inhibitor. Saxagliptin [17,18], vildagliptin [19], alogliptin [20], and linagliptin [21] (Figure 1) are all medications that have either been studied in diabetic patients or approved for sale in some countries. Based on structural similarities or differences with the DPP-IV molecule, DPP-IV inhibitors may be classified as either peptidomimetics (vildagliptin and saxagliptin) or non-peptidomimetics (sitagliptin, alogliptin, linagliptin). They are reversible competitive inhibitors of the DPP-IV substrates. These compounds have various degrees of affinity with DPP-IV substrates. The selectivity of the peptidomimetics toward DPP-IV is often lower as compared to DPP8/9. The greater the relative inhibition of DPP8/9 and the lower the relative selectivity toward DPP-IV, the greater the risk of adverse consequences (allergic skin manifestations, etc.) [22,23]. When compared to non-peptidomimetics, peptidomimetics display a distinct DPP-IV inhibition mechanism. Because non-peptidomimetics generate non-covalent extra-cellular interactions with residues in the catalytic region of the DPP-IV substrate, their inhibiting activity is powerful and rapid. In contrast, inhibition of the DPP-IV substrate by peptidomimetics takes place in a mode that includes the development of a reversible covalent enzyme-inhibitor complex. This complex may be broken down again. This complex binds to and dissociates from the catalytic site of the DPP-IV substrate in a very slow manner, resulting in the persistent inhibition of the DPP-IV enzyme a long time after the medication has been rendered ineffective. Because of this, the catalytic activity is hindered long after the free drug has been eliminated from circulation. In fact, vildagliptin and saxagliptin may be able to suppress DPP-IV activity for a longer period while having relatively short half-lives [24,25].

The usage of gliptin has been proven to be equally effective as compared to metformin, sulfonylureas (glimepiride, glipizide), thiazolidinediones (rosiglitazone, pioglitazone), and alpha-glucosidase inhibitors (voglibose). Compared to sulfonylureas, this therapy almost never causes hypoglycemia or affects body weight [26–28]. According to the findings of a meta-analysis that compared the effectiveness of sitagliptin and vildagliptin, the reported total HbA1c decrease was ~0.74% and 0.73%, respectively. If the starting HbA1c was superior to 9% instead of 8%, the glycemic results were shown to be more favorable [22]. According to a recent meta-analysis, the use of a gliptin was associated with a larger percentage of patients reaching the HbA1c target of <7% without any weight gain or hypoglycemia [29]. We have thus reviewed here the possible utilization of heterocyclic compounds as DPP-IV inhibitors, with special emphasis on oxadiazoles as potent anti-diabetic agents.
According to the theory, the guanidino group of Arg125 may engage bidentately with two hydrogen bond acceptor and have the potential to take part in bidentate interactions with Arg125. Compound 1 was shown to bind in a bivalent manner with the guanidino group of Arg125, which is a powerful and selective DPP-IV inhibitor. The structures of compounds 1 and 2 are illustrated in Figure 2.

![Figure 1. Structures of clinically-approved DPP-IV inhibitors.](image)

2. Review of Different Heterocyclic Compounds as Potent DPP-IV Inhibitors

Yasufumi Miyamoto et al. [15] used structure-based drug design (SBDD) to modify compound 1 to generate a novel and strong DPP-IV inhibitor for the treatment of T2DM. Using the results of X-ray co-crystallography studies on compound 1 revealed that Arg125 might be a suitable target amino acid residue for obtaining a stronger inhibitory activity. According to the theory, the guanidino group of Arg125 may engage bidentately with two separate hydrogen bond acceptors at the same time. As a result, scientists have synthesized a number of 3-pyridylacetamide derivatives that each include an extra hydrogen bond acceptor and have the potential to take part in bidentate interactions with Arg125. Compound 2 was shown to bind in a bivalent manner with the guanidino group of Arg125, which is a powerful and selective DPP-IV inhibitor. The structures of compounds 1 and 2 are illustrated in Figure 2.

![Figure 2. 3-Pyridylacetamide derivatives as DPP-IV inhibitors.](image)

Utilizing the SAR of pyrrole-2-carbonitrile inhibitors, a variety of new hetero-aromatic moiety-substituted amino pyrrole-2-carbonitrile derivatives were synthesized. IC₅₀ values ranged from 0.004 to 113.6 µM for all drugs, indicating that they were effective DPP-IV inhibitors. Compounds 3 (IC₅₀ = 0.004 µM) and 4 (IC₅₀ = 0.01 µM) were found to have excellent inhibitory activities against DPP-IV and a good efficacy in an oral glucose tolerance test (OGTT) in mice. Moreover, compounds 3 and 4 exhibited intermediate pharmacokinetic characteristics (3, F% = 37.8%, t₁/₂ = 1.45 h; 4, F% = 16.8%, t₁/₂ = 3.64 h). The structures of compounds 3 and 4 are displayed in Figure 3 [30].
New beta-amino pyrrole-2-carbonitrile derivatives have been discovered and developed using the rational drug design approach. Compounds 5 and 6 (Figure 4) were reported to be powerful and specific DPP-IV inhibitors in vivo, leading to a reduction in glucose amounts in the blood. Compound 5 significantly inhibited DPP-IV (IC$_{50}$ = 0.05 μM), and also displayed a high oral bioavailability (F = 53.2%). Compound 6 demonstrated strong DPP-IV inhibitory action (IC$_{50}$ = 0.01 μM), high selectivity against related peptidases, good effectiveness during the oral glucose tolerance test (OGTT) in ICR mice, and a moderate pharmacokinetic profile [31].

Figure 4. β-amino pyrrole-2-carbonitrile analogues.

A novel family of 1,2,3-Triazole-4-carboximidamide compounds was successfully developed for their DPP-IV inhibitory activity. When compared to the other drugs examined, compounds 7, 8, and 9 (Figure 5) displayed excellent inhibitory effects against DPP-IV, with IC$_{50}$ values of 14.75, 6.75, and 6.57 nM, respectively. Compound 7, at a dose of 10 mg/kg, enhanced glucose tolerance during OGTT in mice. Chronic treatment with compound 7 for 14 days in diabetic Wistar rats resulted in a significant drop in blood glucose levels, equivalent to the impact of Sitagliptin employed as a conventional treatment [32].

Figure 5. 1,2,3-Triazole-4-carboximidamide derivatives.

Six viable compounds were found using SBDD methods, and it was determined that compound 10 (Figure 6) had the highest docking score, i.e., $-10.463$ K.cal/mol with the DPP-IV enzyme (PDB ID-2ONC). Molecular dynamics (MD) simulations were also used to confirm the protein–ligand complex’s stability. Alogliptin and compound 10 were revealed to have a root-mean-square deviation (RMSD) smaller than 2.0 Å [33].
Owing to their unique properties, oxadiazoles have attracted the attention of scientists in the disciplines of polymer and material science. These compounds feature five-membered rings comprised of two carbons, two nitrogens, and one oxygen atom.

3. Oxadiazoles as Potential Nuclei

Owing to their unique properties, oxadiazoles have attracted the attention of scientists in the disciplines of polymer and material science. These compounds feature five-membered rings comprised of two carbons, two nitrogens, and one oxygen atom.
The number of patent applications for oxadiazoles has climbed to a total of 646 over the last nine years. This suggests that the scientific community has attached great importance to this class of chemicals [36]. Zibotentan, a potential anticancer agent, and ataluren (Figure 10), a potential therapeutic for cystic fibrosis, are two examples of oxadiazole-containing compounds that are now participating in late-stage clinical studies [37]. The only compound available on the market that currently contains oxadiazole is an antiviral drug called raltegravir (Figure 10), which is used to treat HIV infection [38].

Oxadiazoles are now being included in an increasing number of therapeutic approaches in a wide range of disease areas, including but not limited to diabetes [39], obesity [40], inflammation [41], cancer [42], and infection [43].

![Figure 9. Several regioisomeric forms of oxadiazole rings.](image)

A wide array of applications have been found for oxadiazole rings in drug development projects. It has been shown that including them in the pharmacophore improves ligand binding in various ways. The carbonyl groups of molecules such as esters, amides, carbamates, and hydrogenated hydroxamic esters may be replaced with oxadiazoles, constituting another use for these types of molecules [44–46].

Oxadiazole rings exist in form of numerous regioisomers, including 1,2,4-, 1,3,4-, and 1,2,5-isomers (Figure 9). Because the side chains R1 and R2 of the 1,2,5-regioisomer are orientated in a different way compared to that of the side chains in the other two isomers, this isomer is found less often. Oxadiazoles may display different regioisomeric configurations, but they always contain the same R1 and R2 side chains. As a consequence, the positions of these side chains are quite similar. It is envisaged that matching pairings would have identical overall molecular structures and, as a result, would form bonds in the same way. The exceptional hydrogen bond acceptor properties of oxadiazoles and the distinct hydrocarbon bonding potentials of their regioisomers have been established [47–49]. We will now investigate how oxadiazoles may help in treating diabetes.

3. An Overview of the Potential Use of Oxadiazole Derivatives as Anti-Diabetic Drugs

1,3,4-Oxadiazole and 1,2,4-oxadiazole have the potential to be used for many therapeutic applications [50–56].

Omarigliptin is a sulfonamide-containing moiety that inhibits the DPP-IV enzyme to achieve its antihyperglycemic activity [57]. Investigations into its pharmacokinetic properties have shown that it may be given on a once-weekly basis, which distinguishes it from all other DPP-IV inhibitors. The derivatives of 2-cyanoppyrrolidine are classified as glycine-based inhibitors, which fall within the larger category of peptidomimetic inhibitors [58,59]. The presence of a nitrile group on the five-membered pyrrolidine ring in 2-cyanoppyrrolidine derivatives is indicative of their capacity to exert reversible nanomolar

![Figure 10. Oxadiazole structure-containing drugs.](image)
inhibition of the DPP-IV enzyme [60]. We reasoned that compounds based on oxadiazoles would be able to provide an alternative therapy for diabetes for not only controlling glucose levels but also preventing the progression of atherosclerosis and other complications associated with diabetes.

Kumar et al. [61] discovered that some 2-((benzothiazol-2-ylthio)methyl)-5-phenyl-1,3,4-oxadiazole derivatives have the potential to act as anti-diabetic compounds. Using glibenclamide as the reference, each of the synthetic compounds were evaluated for their capacity to combat diabetes in an animal model. At a dose of 350 mg/kg p.o., compound 13 (Figure 11) displayed the most noticeable effect of all molecules, even though all showed a significant activity (orally).

![Figure 11. Benzothiazole tethered with 1,3 4-oxadiazole derivatives as an anti-diabetic oxadiazole derivative.](image)

Benzothiazole-1,3,4-oxadiazole-4-thiazolidinone hybrid derivatives were synthesized by Bhutani et al. [62]. OGTT in non-diabetic rats and streptozotocin-induced diabetic rat models were used to evaluate seven compounds with the highest docking scores. The blood glucose levels were significantly reduced with all of the studied compounds, ranging from good to moderate. The anti-diabetic effects of the three compounds (14, 15 and 16, Figure 12) were superior to those of the conventional medicine pioglitazone, showing a glucose concentration of 178.32 ± 1.88 mg/dL, compared to the lower concentrations of glucose of 157.15 ± 1.79 mg/dL, 154.39 ± 1.71 mg/dL, and 167.36 ± 2.45 mg/dL reported for 14–16. Acarbose (IC$_{50}$ = 18.5 ± 0.20 µM) was found to be the most potent inhibitor of alpha-glucosidase among the seven derivatives examined. However, three of its derivatives, compounds 14, 17, and 18 (Figure 12), displayed lower IC$_{50}$ values (0.21 ± 0.01 µM, 9.03 ± 0.12 µM and 11.96 ± 0.40 µM, respectively), suggesting that they were less effective than the ordinary acarbose. In other words, these innovative hybrids could be used as a basis for the development of novel agents [62].

![Figure 12. Synthetic analogues of benzothiazole-1,3,4-Oxadiazole-4-thiazolidinone.](image)
New 5-(2,2,2-trifluoroethoxy)phenyl-1,3,4-oxadiazol-2-thiol derivatives have been synthesized and analyzed for their biological activities in vitro and in vivo. In comparison to acarbose ($IC_{50} = 34.71 \mu g/mL$), these compounds showed $\alpha$-amylase inhibitory activities in the $IC_{50}$ range of 40.00–80.00 $\mu g/mL$. Compounds 19 and 20 were the ones that exhibited the highest levels of activity in vitro compared to the other synthesized compounds. Animal experiments showed that compounds 19, 20, and 21 (Figure 13) were able to reduce glucose levels in Drosophila, but displayed a 17–30% lower capacity than acarbose. It was shown that compounds 19 and 20 exhibited the highest activity among the produced compounds. In this study, compounds 19, 20, and 21 were revealed to be good candidates for further research as possible anti-diabetes drugs [63].

Figure 13. 1,3,4-Oxadiazole-2-thiol derivatives.

New benzothiazoles clubbed oxadiazole-Mannich bases (M-1 to M-22) synthesized by Bhutani et al. were evaluated using OGTT and STZ-induced diabetes in normal rats. Glucose levels were reduced with compound M-14 (22, Figure 14) (161.39 ± 4.38 mg/dL) in the STZ model, which was equivalent to treatment with glibenclamide (140.29 ± 1.24 mg/dL). The antihyperglycemic efficacy of the other substances tested ranged from fair to excellent [64].

Figure 14. Benzothiazole clubbed oxadiazole-Mannich base.

Nordhoff et al. [65] demonstrated that amide substitutions enhanced the absorption, distribution, metabolism, and excretion (ADME) characteristics of a series of $\beta$-homophenylalanine-based inhibitors of DPP-IV. Thanks to the efforts of this group, a new class of powerful and selective DPP-IV inhibitors with an appealing pharmacokinetic profile and good performance was synthesized and evaluated in an animal model of diabetes.
Compounds 23 and 24 (Figure 15) from this new series of compounds were shown to display interesting pharmacokinetic properties and to work very well in animal models of diabetes.

![Figure 15. β-homophenylalanine-based inhibitors of DPP-IV.](image)

A new class of powerful, selective, and orally accessible DPP-IV inhibitors has been discovered by Xu et al. [66] Without an electrophilic trap, they are among the most powerful chemicals known to date. Regarding DPP-IV homologs, compound 25 (Figure 16) was shown to have a higher selectivity. However, their short half-life, observed after oral treatment in rats and dogs, led to further research being stopped on these compounds.

![Figure 16. 1,2,4-Oxadiazole derivative as a potent DPP-IV inhibitor.](image)

N-aryl/aralkyl derivatives of 2-methyl-2-[5-(4-chlorophenyl)-1,3,4-oxadiazole-2-ylthiol] acetamides were synthesized and the α-glucosidase inhibitory potential of each drug was examined. Compounds 26-31 (Figure 17) displayed a strong α-glucosidase inhibitory activity (IC$_{50}$ of 81.72 ± 1.18, 52.73 ± 1.16, 62.62 ± 1.15, 56.34 ± 1.17, 86.35 ± 1.17, 52.63 ± 1.16 μM, respectively). These results were validated by molecular modelling and ADME predictions. It was then possible to synthesize a library of compounds using ordinary basic materials possibly leading to the development of new medicines [67].

One-pot multicomponent design and synthesis of three series of diamine-bridged bis-coumarinyl oxadiazole conjugates were reported by Kazmi et al. [68]. The conjugates produced were tested for their ability to inhibit glucosidas. With an IC$_{50}$ value of only 0.07 ± 0.001 μM (acarbose: 38.2 ± 0.12 μM), compound 32 (Figure 18), including the 4,4′-oxydianiline linker, was shown to be the primary and selective inhibitor of α-glucosidase enzymes. Its inhibitory activity was about 545 times higher compared to conventional drugs. Compound 32 was also shown to be a strong inhibitor of intestinal maltase-glucoamylase (IC$_{50}$ = 0.04 ± 0.02 μM) compared to acarbose (IC$_{50}$ = 0.06 ± 0.01 μM). With an IC$_{50}$ value of 0.08 ± 0.002 μM, this compound was reported to be the primary inhibitor of the β-glucosidase enzyme. The mechanism of the inhibition was investigated using Michaelis–Menten kinetic studies. All the generated molecules were docked against the glucosidase enzyme. According to the obtained results, numerous interactions were observed with catalytic residues in a coordinated manner, which might stabilize inhibitors in
the active site. In addition, β-glucosidase inhibitors were successfully identified via the use of molecules having strong binding interactions with amino acid residues.

![Figure 17](image1.png)

**Figure 17.** Oxadiazole derivatives with strong α-glucosidase inhibitory activity.

![Figure 18](image2.png)

**Figure 18.** Anti-diabetic drugs derived from diamine-bridged coumarinyl oxadiazoles.

Taha et al. [69] designed and synthesized twenty 5-aryl-2-(6′-nitrobenzofuran-2′-yl)-1,3,4-oxadiazole derivatives and tested them for their ability to inhibit α-glucosidase. Compared to acarbose (IC$_{50}$ = 856.45 ± 5.60 μM), compounds with hydroxyl groups and halogens (compounds 33–38, Figure 19) were shown to be five to seventy times more active, with IC$_{50}$ values in the range of 12.75 ± 0.10 to 162.05 ± 1.65 μM. A hybrid family of oxadiazole and benzofuran compounds is now being studied for its ability to block α-glucosidase. Researchers may be prompted to use these results for the treatment of hyperglycemia. Within docking studies, hydrogen bonds and arene–arene interactions were shown to be the primary means of interactions with Glu 276, Asp 214, and Phe 177.

![Figure 19](image3.png)

**Figure 19.** Nitrobenzofuran-1,3,4-Oxadiazoles derivatives.
Anti-diabetic drugs derived from 1,3,4-oxadiazoles have been discovered by Ullah et al. [70]. The ability of these newly synthesized compounds to inhibit α-glucosidase activity was investigated. As compared to acarbose (38.45 ± 0.80 μM), all compounds showed strong inhibitory activities with IC_{50} values ranging from 0.80 ± 0.1 to 45.1 ± 1.7 μM. Thirteen compounds revealed potential inhibitory actions, though only one molecule (IC_{50} = 45.1 ± 1.7 μM) was found to be less active. Among all the synthesized derivatives, one compound (IC_{50} = 0.80 ± 0.1 μM) demonstrated the most promising inhibitory efficacy.

Taha et al. [71] discovered hybrid analogues of oxindole-based oxadiazoles (based on the structure of compound 39, Figure 20) as potential α-glucosidase inhibitors. As compared to acarbose (IC_{50} = 895.09 ± 2.04 μM), all compounds were shown to be powerful inhibitors of this enzyme, with IC_{50} values ranging from 1.25 ± 0.05 to 268.36 ± 4.22 μM. In this work, a new series of powerful α-glucosidase inhibitors have been discovered, suggesting further investigations.

![Image of compound 39](image.png)

**Figure 20.** α-Glucosidase inhibitors based on oxadiazole hybrids.

New 1,2,4-oxadiazole derivatives, whose structures were reported in the US patent issued by Xu et al. [72] (compound 40, Figure 21), are DPP-IV enzyme inhibitors and may be used to treat or prevent disorders involving this enzyme, such as diabetes, and more specifically type 2 diabetes. A pharmaceutical composition including these compounds and their application in the prevention or treatment of illnesses involving the DPP-IV enzyme are also contemplated by this invention.

![Image of compound 40](image.png)

**Figure 21.** DPP-IV inhibitors derived from 1,2,4-oxadiazole.

Hamdani et al. [73] synthesized three 1,3,4-oxadiazole derivatives (compounds 41, 42, and 43, Figure 22) and used X-ray diffraction, density functional theory (DFT), and other methods to demonstrate their inhibitory potential of α-amylase. X-ray diffraction and other spectro-analytical methods were employed to validate the structures of the obtained compounds, which were prepared in excellent yields (70–83%). In addition to validating X-ray data, DFT calculations also examined charge dispersion and reactivity,
utilizing frontier molecular orbitals and molecular electrostatic potential (MEP) approaches. α-amylase inhibition experiments were used to determine the enzymatic inhibitory capacity of the produced compounds (41, 42, and 43). Compound 42 displayed a low IC50 value of 86.83 ± 0.23 μg/mL, which indicates its strong ability to inhibit α-amylase.

Figure 22. Inhibitors of alfa-amylase activity based on 1,3,4-oxadiazole derivatives.

The anti-diabetic properties of oxadiazole derivatives were studied in silico using the DFT approach, employing the B3LYP version with compounds set by Ibrahim et al. [74]. Four models were generated using the Genetic Function Algorithm (GFA). Based on the obtained results, researchers determined that Model 1 had the highest LOF (0.030552), R2 (0.09681), R2adj (0.09567), Q2CV (0.09364), and R2 (0.06969) values. Findings from molecular docking indicated that few ligands had the greatest docking scores of −9.9 kcal/mol among the co-ligands. The docking ratings produced here were shown to be in concordance with findings from previous studies. As a result of this work, anti-diabetic drugs with improved inhibitory action against α-glucosidase could potentially be developed.

In order to investigate the sequential conversion of indolyl butanoic acid into 1,3,4-oxadiazole-2-thiols, Nazir et al. [75] employed several chemical transformations. Several different amine derivatives were reacted with 2-bromoacetyl bromide to serve as an electrophile, leading to the production of 2-bromo-N-phenyl/arylacetamides in a series of operations that ran in parallel with one another. A nucleophilic 1,3,4-oxadiazole-2-thiol analogue was then applied to the electrophilic compounds to produce a variety of N-substituted derivatives (compounds 44a and 44b, Figure 23). In this study, the anti-diabetic potential of all produced compounds was first examined through the inhibition of the α-glucosidase enzyme, and then by studying them in silico. In addition, their hemolytic activity was used to determine their cytotoxicity profile, and all of the compounds were shown to display minimal cytotoxicity. The most active compounds (44a and 44b) had IC50 values of 9.46 ± 0.03 μM and 9.37 ± 0.03 μM, respectively. As a result, they may serve in future studies to develop more efficient anti-diabetic drugs, as they showed excellent to moderate inhibitory potentials (IC50 = 12.68 ± 0.04 to 37.82 ± 0.07 μM, respectively).

Figure 23. Derivatives of the 1,3,4-oxadiazole-2-thiol compound.

4. Structural Activity Relationship (SAR)

A brief structural activity relationship (SAR) is depicted in Figure 24. It was observed that almost all the potent derivatives were found to hold substitutions with different heterocyclic compounds or alkyl groups. Substitution with benzothiazoles and thiazolidinones leads to potent in vivo activity and displays significant overall anti-diabetic activities. The transformation of oxadiazole into the acetamido functional group has led to the devel-
opment of potential anti-diabetic agents, which were revealed as excellent DPP-IV inhibitors. However, many more substitutions, such as aminophenyl, β-homophenylalanine, coumarinyl, nitrobenzofuran, oxindole, trifluorophenyl-thiol, etc., could act as potential anti-diabetic agents, and especially as potential DPP-IV inhibitors.

This study, the anti-diabetic potential of all produced compounds was first examined through the inhibition of the α-glucosidase enzyme, and then by studying them in silico. In addition, their hemolytic activity was used to determine their cytotoxicity profile, and all of the compounds were shown to display minimal cytotoxicity. The most active compounds (44a and 44b) had IC50 values of 9.46 ± 0.03 μM and 9.37 ± 0.03 μM, respectively. As a result, they may serve in future studies to develop more efficient anti-diabetic drugs, as they showed excellent to moderate inhibitory potentials (IC 50 = 12.68 ± 0.04 to 37.82 ± 0.07 μM, respectively).

Figure 23. Derivatives of the 1,3,4-oxadiazole-2-thiol compound.

5. Structural Activity Relationship (SAR)

A brief structural activity relationship (SAR) is depicted in Figure 24. It was observed that almost all the potent derivatives were found to hold substitutions with different heterocyclic compounds or alkyl groups. Substitution with benzothiazoles and thiazolidinones leads to potent in vivo activity and displays significant overall anti-diabetic activities. The transformation of oxadiazole into the acetamido functional group has led to the development of potential anti-diabetic agents, which were revealed as excellent DPP-IV inhibitors. However, many more substitutions, such as aminophenyl, β-homophenylalanine, coumarinyl, nitrobenzofuran, oxindole, trifluorophenyl-thiol, etc., could act as potential anti-diabetic agents, and especially as potential DPP-IV inhibitors.

Figure 24. Predicted SAR of oxadiazoles.

5. Conclusion

1,3,4-Oxadazole and 1,2,4-oxadiazole derivatives can be used in a variety of ways within the medical sector. Oxadiazoles possess diverse pharmacological activities, including anti-diabetic potential, and specifically acting as DPP-IV inhibitors. It has been reported that oxadiazoles fused with benzothiazoles, 5-(2,2,2-trifluoroethoxy)phenyl, β-homophenylalanine, 2-methyl-2-(5-(4-chlorophenyl), diamine-bridged bis-coumarinyl, 5-aryl-2-(6'-nitrobenzofuran-2'-yl), nitrobenzofuran, and/or oxindoles demonstrate potential anti-diabetic activities. Furthermore, the most potent derivatives were obtained by substituting sulfur-containing heterocyclic compounds, as the sulfur atom has the potential to form interactions with the target enzymes. It was observed that almost all the potent derivatives were found to possess substitutions with different heterocyclic compounds or alkyl groups. Many of these derivatives induced strong conformational changes to the DPP-IV enzyme, resulting in excellent anti-diabetic activity. From this analysis, we came to the conclusion that oxadiazoles have properties that make them potent drugs. Further research is needed to consider them as valuable drugs to treat diabetes, especially as DPP-IV inhibitors. As discussed above, substitutions at the R1 and R2 positions leads to more potent and effective DPP-IV inhibitors. It may be possible to design some potent derivatives in future by appending different heterocyclic and alkyl groups at the R1 and R2 positions. It is a great challenge to maintain the binding mode of the derivatives following substitutions. After substitution, each derivative can be screened through molecular docking studies to determine its ability to cause conformational changes in the DPP-IV enzyme.

Author Contributions: Conceptualization, B.D.M. and S.L.K.; software, F.A.S., Z.A., F.S.K. and P.T.; validation, B.D.M., M.S.B. and S.L.K.; investigation, N.B. and F.A.S.; resources, B.D.M.; data curation, Z.A., F.S.K. and F.A.S.; writing—original draft preparation, B.D.M., M.S.B., N.B., F.A.S., S.L.K. and P.J.; writing—review and editing, B.D.M., M.S.B., N.B., F.A.S., S.L.K. and P.J.; visualization, S.L.K. and P.T.; supervision, S.L.K.; project administration, P.T., S.L.K. and P.J. All authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors from King Khalid University extend their appreciation to the Deanship of Scientific Research at King Khalid University for funding this work through the Research Groups Program under Grant No. RGP2/229/43.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Jao, C.L.; Hung, C.C.; Tung, Y.S.; Lin, P.Y.; Chen, M.C.; Hsu, K.C. The Development of Bioactive Peptides from Dietary Proteins as a Dipeptidyl Peptidase IV Inhibitor for the Management of Type 2 Diabetes. *Biomedicine* 2015, 5, 9–15. [CrossRef]

2. Green, B.D.; Flatt, P.R.; Bailey, C.J. Dipeptidyl Peptidase IV (DPP IV) Inhibitors: A Newly Emerging Drug Class for the Treatment of Type 2 Diabetes. *Diabetes Vasc. Dis. Res.* 2006, 3, 159–163. [CrossRef] [PubMed]

3. Lovshin, J.A.; Zinman, B. Blood Pressure-Lowering Effects of Incretin-Based Diabetes Therapies. *Can. J. Diabetes* 2014, 38, 364–371. [CrossRef]

4. Tomovic, K.; Lazarevic, J.; Kocic, G.; Deljanin-Ilic, M.; Anderluh, M.; Smelcerovic, A. Mechanisms and Pathways of Anti-Inflammatory Activity of DPP-4 Inhibitors in Cardiovascular and Renal Protection. *Med. Res. Rev.* 2019, 39, 404–422. [CrossRef] [PubMed]

5. Nagamine, A.; Hasegawa, H.; Hashimoto, N.; Yamada-Inagawa, T.; Hirose, M.; Kobara, Y.; Tadokoro, H.; Kobayashi, Y.; Takano, H. The Effects of DPP-4 Inhibitor on Hypoxia-Induced Apoptosis in Human Umbilical Vein Endothelial Cells. *J. Pharmacol. Sci.* 2017, 133, 42–48. [CrossRef]

6. Fadini, G.P.; Avogaro, A. Cardiovascular Effects of DPP-4 Inhibition: Beyond GLP-1. *Vasc. Pharmacol.* 2011, 55, 10–16. [CrossRef]

7. Steven, S.; Frenis, K.; Oelze, M.; Kalinovic, S.; Kuntic, M.; Jimenez, M.T.B.; Vujacic-Mirski, K.; Helmstädt, J.; Kröller-Schön, S.; Münnzel, T.; et al. Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease. *Oxid. Med. Cell. Longev.* 2019, 2019, 7092151. [CrossRef]

8. Singh, A.K.; Yadav, D.; Sharma, N.; Jin, J.O. Dipeptidyl Peptidase (Dpp)-iv Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes. *Pharmaceuticals* 2021, 14, 586. [CrossRef] [PubMed]

9. Singh, A.K.; Jatwa, R.; Purohit, A.; Ram, H. Synthetic and Phytocompounds Based Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors for Therapeutics of Diabetes. *J. Asian Nat. Prod. Res.* 2017, 19, 1036–1045. [CrossRef] [PubMed]

10. Nash, R.J.; Kato, A.; Yu, C.Y.; Fleet, G.W. Iminosugars as Therapeutic Agents: Recent Advances and Promising Trends. *Future Med. Chem.* 2011, 3, 1513–1521. [CrossRef] [PubMed]

11. Horne, G.; Wilson, F.X.; Tinsley, J.; Williams, D.H.; Storer, R. Iminosugars Past, Present and Future: Medicines for Tomorrow. *Drug Discov. Today* 2011, 16, 107–118. [CrossRef] [PubMed]

12. Verma, A.K.; Dubbu, S.; Chennaiah, A.; Vankar, Y.D. Synthesis of Di- and Trisubstituted Pyrrolizidines and Biactive 1C-Aryl/Alkyl Pyrrolidines. *Carbohydr. Res.* 2019, 475, 48–55. [CrossRef] [PubMed]

13. Chennaiah, A.; Bhowmick, S.; Vankar, Y.D. Conversion of Glycals into Vicinal-1,2-Diazides and 1,2-(or 2,1)-Azidocacetates Using Hypervalent Iodine Reagents and Me3SiN3. Application in the Synthesis of: N-Glycopeptidases, Pseudo-Trisaccharides and an Iminosugar. *RSC Adv.* 2017, 7, 41755–41762. [CrossRef]

14. Chennaiah, A.; Dahiya, A.; Dubbu, S.; Vankar, Y.D. A Stereoselective Synthesis of an Imino Glycal: Application in the Synthesis of (−)-1-Epi-Adenophorine and a Homoinosugar. *Eur. J. Org. Chem.* 2018, 2018, 6574–6581. [CrossRef]

15. Miyamoto, Y.; Banno, Y.; Yamashita, T.; Fujimoto, T.; Oi, S.; Moritoh, Y.; Asakawa, T.; Kataoka, O.; Takeuchi, K.; Suzuki, N.; et al. Design and Synthesis of 3-Pyridylacetamide Derivatives as Dipeptidyl Peptidase IV (DPP-4) Inhibitors Targeting a Bidentate Interaction with Arg125. *Bioorg. Med. Chem.* 2011, 19, 172–185. [CrossRef]

16. Jiang, J.H.; Kuo, C.H.; Liu, Y.H.; Chang, H.Y.; Chen, C.T. Effects of Dipeptidyl Peptidase-4 Inhibition with MK-0431 on Syngeneic Mouse Islet Transplantation. *Int. J. Endocrinol.* 2014, 2014, 795283. [CrossRef]

17. Borja-Hart, N.L.; Whalen, K.L. Saxagliptin: A New Dipeptidyl Peptidase 4 Inhibitor for Type 2 Diabetes. *Amn. Pharmacother.* 2010, 44, 1046–1053. [CrossRef]

18. Augeri, D.J.; Robl, J.A.; Betebenner, D.A.; Magnin, D.R.; Khanna, A.; Robertson, J.G.; Wang, A.; Simpkins, L.M.; Taunk, P.; Huang, Q.; et al. Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes. *J. Med. Chem.* 2005, 48, 5025–5037. [CrossRef]

19. Barnett, A. DPP-4 Inhibitors and Their Potential Role in the Management of Type 2 Diabetes. *Int. J. Clin. Pract.* 2006, 60, 1454–1470. [CrossRef]
20. Inagaki, N.; Omouchi, H.; Sano, H.; Funao, N.; Kuroda, S.; Kaku, K. SYR-472, a Novel Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, in Type 2 Diabetes Mellitus: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial. *Lancet Diabetes Endocrinol.* 2014, 2, 125–132. [CrossRef]

21. Gomes, G.K.A.; Pereira, M.L.; Sanches, C.; Baldoni, A.O. Post-Marketing Study of Linagliptin: A Pilot Study. *Front. Pharmacol.* 2019, 10. [CrossRef]

22. Amori, R.E.; Lau, J.; Pittas, A.G. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-Analysis. *J. Am. Med. Assoc.* 2007, 298, 194–206. [CrossRef]

23. Cao, G.Y.; Li, X.C.; Zhao, N.; Liu, Q.; Hu, X. Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes. *Chin. J. New Drugs* 2011, 20, 497–502. [CrossRef]

24. Drucker, D.J. The Biology of Incretin Hormones. *Cell Metab.* 2006, 3, 153–165. [CrossRef]

25. Holst, J.J. The Physioloogy and Pharmacology of Incretins in Type 2 Diabetes Mellitus. *Diabetes Obes. Metab.* 2008, 10, 14–21. [CrossRef]

26. Saisho, Y. Alogliptin Benzoate for Management of Type 2 Diabetes. *Vasc. Health Risk Manag.* 2015, 11, 229–243. [CrossRef]

27. Pratley, R.E. Alogliptin: A New, Highly Selective Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes. *Expert Opin. Pharmacother.* 2009, 10, 503–512. [CrossRef]

28. Mohan, V.; Yang, W.; Son, H.Y.; Xu, L.; Noble, L.; Langdon, R.B.; Amatruda, J.M.; Stein, P.P.; Kaufman, K.D. Efficacy and Safety of Sitagliptin in the Treatment of Patients with Type 2 Diabetes in China, India, and Korea. *Diabetes Res. Clin. Pract.* 2009, 83, 106–116. [CrossRef]

29. Esposito, K.; Cozzolino, D.; Bellastella, G.; Maiorino, M.I.; Chiodini, P.; Ceriello, A.; Giugliano, D. Dipeptidyl Peptidase-4 Inhibitors and HbA1c Target of <7% in Type 2 Diabetes: Meta-Analysis of Randomized Controlled Trials. *Diabetes Obes. Metab.* 2011, 13, 594–603. [CrossRef] [PubMed]

30. Ji, X.; Su, M.; Wang, J.; Deng, G.; Deng, S.; Li, Z.; Tang, C.; Li, J.; Li, J.; Zhao, L.; et al. Design, Synthesis and Biological Evaluation of Hetero-Aromatic Moieties Substituted Pyrrole-2-Carbonitrile Derivatives as Dipeptidyl Peptidase IV Inhibitors. *Eur. J. Med. Chem.* 2014, 75, 111–122. [CrossRef] [PubMed]

31. Li, J.; Ji, X.; Xia, C.; Wang, J.; Su, M.; Zhang, L.; Dong, T.; Li, Z.; Wan, X.; Li, J.; et al. Design, Synthesis and Biological Evaluation of 4-Fluoropyrrolidine-2-Carbonitrile and Octahydrocyclopenta[b]Pyrrole-2-Carbonitrile Derivatives as Dipeptidyl Peptidase IV Inhibitors. *Eur. J. Med. Chem.* 2014, 86, 242–256. [CrossRef]

32. Dastjerdi, H.F.; Naderi, N.; Nemiatpour, M.; Rezaee, E.; Mahboubi-Rabbani, M.; Ebrahimi, M.; Hosseinpour, S.; Hosseini, O.; Tabatabai, S.A. Design, Synthesis and Anti-Diabetic Activity of Novel 1, 2, 3-Triazole-5-Carboximidamide Derivatives as Dipeptidyl Peptidase-4 Inhibitors. *J. Mol. Struct.* 2020, 1221. [CrossRef]

33. Nath, V.; Ramchandani, M.; Kumar, N.; Agrawal, R.; Kumar, V. Computational Identification of Potential Dipeptidyl Peptidase (DPP)-IV Inhibitors: Structure Based Virtual Screening, Molecular Dynamics Simulation and Knowledge Based SAR Studies. *J. Mol. Struct.* 2021, 1224, 129006. [CrossRef]

34. Huang, J.; Deng, X.; Zhou, S.; Wang, N.; Qin, Y.; Meng, L.; Li, G.; Xiong, Y.; Fan, Y.; Guo, L.; et al. Identification of Novel Uracil Derivatives Incorporating Benzoic Acid Moieties as Highly Potent Dipeptidyl Peptidase-4 Inhibitors. *Bioorg. Med. Chem.* 2019, 27, 644–654. [CrossRef] [PubMed]

35. Li, Q.; Deng, X.; Jiang, N.; Meng, L.; Xing, J.; Jiang, W.; Xu, Y. Identification and Structure–Activity Relationship Exploration of Uracil-Based Benzoic Acid and Ester Derivatives as Novel Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus. *Eur. J. Med. Chem.* 2021, 225, 113765. [CrossRef] [PubMed]

36. Pace, A.; Pierro, P. The New Era of 1,2,4-Oxadiazoles. *Org. Biomol. Chem.* 2009, 7, 4337–4348. [CrossRef] [PubMed]

37. Jones, A.M.; Helm, J.M. Emerging Treatments in Cystic Fibrosis. *Drugs* 2009, 69, 1903–1910. [CrossRef]

38. Summa, V.; Petrocchi, A.; Bonelli, F.; Crescenzi, B.; Donghi, M.; Ferrara, M.; Fiore, F.; Gardelli, C.; Paz, O.G.; Hazuda, D.J.; et al. Discovery of Rotalgegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection. *J. Med. Chem.* 2008, 51, 5843–5855. [CrossRef]

39. Jones, R.M.; Leonard, J.N.; Buzard, D.J.; Lehmann, J. GPR119 Agonists for the Treatment of Type 2 Diabetes. *Expert Opin. Ther. Pat.* 2009, 19, 1339–1359. [CrossRef]

40. Suk, H.L.; Hee, J.S.; Lee, S.H.; Myung, E.J.; Park, J.H.; Park, H.J.; Yoo, J.; Yun, H.; Na, J.; Suk, Y.K.; et al. Barylpyrazolyl Oxadiazole as Potent, Selective, Orally Bioavailable Cannabinoid-1 Receptor Antagonists for the Treatment of Obesity. *J. Med. Chem.* 2008, 51, 7216–7233. [CrossRef]

41. Unangst, P.C.; Shrum, G.P.; Connor, D.T.; Dyer, R.D.; Schrier, D.J. Novel 1,2,4-Oxadiazoles and 1,2,4-Thiadiazoles as Dual 5-Lipoxygenase and Cyclooxygenase Inhibitors. *J. Med. Chem.* 1992, 35, 3691–3698. [CrossRef]

42. Zhang, H.Z.; Kasibhatla, S.; Kuenmerle, J.; Kemnitzer, W.; Ollis-Mason, K.; Qiu, L.; Crogan-Grundy, C.; Tseng, B.; Drewes, J.; Cai, S.X. Discovery and Structure-Activity Relationship of 3-Aryl-5-Aryl-1,2,4-Oxadiazoles as a New Series of Apoptosis Inducers and Potential Anticancer Agents. *J. Med. Chem.* 2005, 48, 5215–5223. [CrossRef]

43. Cottrell, D.M.; Capers, J.; Salem, M.M.; DeLuca-Fradley, K.; Croft, S.L.; Werbovetz, K.A. Antikinetoplastid Activity of 3-Aryl-5-Thiocyanoantimethyl-1,2,4-Oxadiazoles. *Bioorg. Med. Chem.* 2004, 12, 2815–2824. [CrossRef]

44. Ohmoto, K.; Okuma, M.; Yamamoto, T.; Kijima, H.; Sekioka, T.; Kitagawa, K.; Yamamoto, S.; Tanaka, K.; Kawabata, K.; Sakata, A.; et al. Design and Synthesis of New Orally Active Inhibitors of Human Neutrophil Elastase. *Bioorg. Med. Chem.* 2001, 9, 1307–1323. [CrossRef]
68. Kazmi, M.; Zaib, S.; Ibrar, A.; Amjad, S.T.; Shafique, Z.; Mehsud, S.; Saeed, A.; Iqbal, J.; Khan, I. A New Entry into the Portfolio of α-Glucosidase Inhibitors as Potent Therapeutics for Type 2 Diabetes: Design, Bioevaluation and One-Pot Multi-Component Synthesis of Diamine-Bridged Coumarinyl Oxadiazole Conjugates. *Bioorg. Chem.* 2018, 77, 190–202. [CrossRef]

69. Taha, M.; Ismail, N.H.; Imran, S.; Wadood, A.; Rahim, F.; Saad, S.M.; Khan, K.M.; Nasir, A. Synthesis, Molecular Docking and α-Glucosidase Inhibition of 5-Aryl-2-(6′-Nitrobenzofuran-2′-Yl)-1,3,4-Oxadiazoles. *Bioorg. Chem.* 2016, 66, 117–123. [CrossRef]

70. Ullah, H.; Rahim, F.; Taha, M.; Hussain, R.; Wadood, A.; Nawaz, M.; Wâhab, Z.; Kanwal; Khan, K.M. Synthesis, In Vitro α-Glucosidase Inhibitory Potential and Molecular Docking Studies of 2-Amino-1,3,4-Oxadiazole Derivatives. *Med. Chem.* 2019, 16, 724–734. [CrossRef]

71. Taha, M.; Imran, S.; Rahim, F.; Wadood, A.; Khan, K.M. Oxindole Based Oxadiazole Hybrid Analogs: Novel α-Glucosidase Inhibitors. *Bioorg. Chem.* 2018, 76, 273–280. [CrossRef]

72. Xu, J.; Wei, L.; Mastracchio, A.; Edmondson, S. (12) Patent Application Publication (10). U.S. Patent 2008/0225123. A1 Patent Application Publication. *Priv. Point Contain. Sm. Card* 2008, 1, 11–14.

73. Hamdani, S.S.; Khan, B.A.; Ahmed, M.N.; Hameed, S.; Akhter, K.; Ayub, K.; Mahmood, T. Synthesis, Crystal Structures, Computational Studies and α-Amylase Inhibition of Three Novel 1,3,4-Oxadiazole Derivatives. *J. Mol. Struct.* 2020, 1200, 127085. [CrossRef]

74. Ibrahim, M.T.; Uzairu, A.; Shallangwa, G.A.; Ibrahim, A. In-Silico Studies of Some Oxadiazoles Derivatives as Anti-Diabetic Compounds. *J. King Saud Univ. Sci.* 2020, 32, 423–432. [CrossRef]

75. Nazir, M.; Abbasi, M.A.; Aziz-ur-Rehman; Siddiqui, S.Z.; Khan, K.M.; Kanwal; Salar, U.; Shahid, M.; Ashraf, M. New Indole Based Hybrid Oxadiazole Scaffolds with N-Substituted Acetamides: As Potent Anti-Diabetic Agents. *Bioorg. Chem.* 2018, 81, 253–263. [CrossRef]